The Hepatitis B e-Antigen Negative Disease - Directly Offered Study of Treatment Withdrawal in Patients With e-Antigen Negative Chronic HBV Infection (BeNEG-DO).

Chronic Hepatitis B Virus Clinical Trial

— BeNEG-DO  

Official title:

"BeNEG-DO": A Study of Clinical Outcomes, Immunologic Correlates and Genetic Predictors After Treatment Withdrawal in e-Antigen Negative (HBeAg-) Chronic Hepatitis B Virus (HBV) Infection

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02845401
• Other study ID #: 1R01DK103735-01A1
• Status: Active, not recruiting
• Phase: N/A
• Start date: November 17, 2016
• Est. completion date: May 31, 2026

Study information

• Verified date: July 2023
• Source: California Pacific Medical Center Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators' research is aimed at developing more effective, finite approaches for managing individual patients with chronic hepatitis B (CHB). This prospective clinical and basic scientific study exclusively focuses on patients with the early antigen negative form of disease, which in developed countries is treated indefinitely with antiviral drugs. The investigators' study "BeNEG-DO," directly offers patients who are already taking standard oral Hepatitis B Virus (HBV) antiviral therapy for at least 192 weeks the option to stop or continue treatment. Drawing on data from pilot studies, including the investigators' own University of California, San Francisco and Sutter Institutional Review Board-approved study, the investigators will examine a finite HBV treatment strategy on clinical outcome and safety. In conjunction, the investigators will study immunologic mechanisms and gene expression profiles that correlate with and predict the post-treatment clinical course. The BeNEG-DO study could seriously question, and potentially change, the current treatment paradigm for millions of patients with CHB and also lead to new disease-terminating antiviral therapeutics.

Description:

A prospective case-control study of safety and clinical outcomes, and of innate and adaptive immune responses and their genetic predictors, in adult human subjects with HBeAg-CHB who either continue or stop nucleoside or nucleotide analog (NA) antiviral therapy. Immune responses will be studied using liver tissue and serial peripheral blood samples. The immunological factors selected have been chosen based on preliminary and inferential evidence. Immunologic findings will be correlated with different serologic, virologic and biochemical outcomes. Genetic predictors of the type of response and respective clinical outcomes will also be sought.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 121
• Est. completion date: May 31, 2026
• Est. primary completion date: May 25, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 67 Years

Eligibility

Inclusion Criteria:

1. HBeAg-CHB with at least 192 weeks (3.7 years) of complete viral suppression (serum HBV DNA <50 IU/ml) on NA therapy

2. No bridging fibrosis (= Metavir stage 3)

3. Normal liver tests and platelet count

4. Age 18-67

5. Otherwise healthy with no serious co-morbidities

6. Patients who are willing, prepared, and able to immediately resume antiviral treatment upon medical instruction and on satisfying study re-treatment criteria.

Exclusion Criteria:

1. HBeAg-CHB with virologic breakthrough while on NA therapy during the prior 192 weeks (3.7 years)

2. Age <18 or >67 years

3. Significant co-morbidities including co-infection and significant co-existing liver disease or anemia. Mild Non-Alcoholic Fatty Liver Disease (NAFLD) without Non-Alcoholic Steatohepatitis (NASH) or associated liver enzyme elevation will be allowed.

4. Bridging hepatic fibrosis (= Metavir stage 3) at the time of potential study entry

a. Control Group: Determination will be based on historical biopsy data, imaging studies, Platelet count (<150,000), Aspartate aminotransferase to Platelet Ratio Index (APRI) <1.5) and Red Cell Distribution Width-to-Platelet Ratio (RPR) (<0.16) scores, and clinical assessment

5. Alanine Aminotransferase (ALT) above the quoted normal range

6. Clinical, serologic, radiological or biochemical suspicion for cirrhosis

7. Prior liver transplantation

8. A documented history of extrahepatic manifestations of hepatitis B, including renal disease and/or vasculitis

9. Cases: A family history of hepatocellular carcinoma due to hepatitis B virus in a first degree family member

10. On Prednisone or other immunosuppressive or immune-modulating therapy during the 6 months before study entry

11. Pregnancy

12. Patients who are not willing, prepared, and able to immediately resume antiviral treatment upon medical instruction and on satisfying re-treatment criteria

No one will be excluded on the basis of race, gender, religion, sexual orientation, or any cultural factor. An Institutional Review Board (IRB)-approved, translated consent will be used for patients that do not speak English

Related Conditions & MeSH terms

• Chronic Hepatitis B Virus
• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic

Intervention

Other:
• Stop NA therapy
Cases will stop antiviral therapy

Locations

Country	Name	City	State
United States	California Pacific Medical Center	San Francisco	California
United States	University of California, San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
California Pacific Medical Center Research Institute	University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serologic response and rate: HBsAg persistence versus loss; HBsAb production (+/-). This clinically relevant endpoint evaluates chronic HBV clearance and persistence	Annual seroclearance rates of 0.5%-0.8% in controls are assumed (American Association for the Study of Liver Diseases 2012 Poster 374) and equivalent to the estimated spontaneous rate (Hepatology 2009; 49:S45-55). In cases, 5-6% (based on Gastroenterology 2012 143:629:636) 5 year rates for HBsAg seroconversion (5%) or HBsAg loss only.	10 years
Secondary	Liver biochemical response: ALT level	These anticipated biochemical outcomes are based on Gastroenterology 2012 143:629-636	5 years
Secondary	Virologic response: HBV DNA level	Hepatitis B Virus levels measured in International Units per milliliter	10 years
Secondary	Case retreatment rate	As a measure of safety	10 years